<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20160307026950N14</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2019-07-18</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>The effect of two drugs succinylcholine and cisatracurium in  electroshock therapy.</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of cardiovascular changes and serum potassium levels in the use of succinylcholine and cisatracurium drugs in electroshock therapy</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2018-12-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>90</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/39750</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Crossover, Purpose: Treatment, Randomization description: .Patients were randomly assigned to two groups A and B, using Random Allocation software, and compared in two Sequence and two Period (AB, BA), Blinding description: Both drugs are prepared by the researcher using syringes of the same form and size, and the person who prescribes the drug and the person who registers the vital signs are different and are unaware of the contents of the packages.</study_design>
      <phase>3</phase>
      <hc_freetext>Condition 1: Succinylcholine Chloride. Condition 2: cisatracurium.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: After obtaining a license from the Medical Ethics Committee of Isfahan University of Medical Sciences, patients who are willing to participate in the study. In the first period  with the package  (b) containing 1.5 mg / kg of ketamine and 50 μg / kg of cis-atracurium and in the second period with the package (a) containing 1.5 mg / kg of ketamine and mg/kg 0.5 of succinylcholine taken under electroshock therapy. And from the right hand, blood samples are taken at the time before administration of the anesthetic drug (baseline) before induction of the electroshock  (after administration of the drug), after the seizure, and 20 minutes after induction of anesthesia. before induction Anesthesia is provided for patients with a simple oxygen mask and given 4 to 6 liters of oxygen for a period of three minutes. Heart monitoring includes electro-cardiogram and heart rate, pulse oximetry and non-invasive blood pressure for all patients. Heart rate, mean arterial blood pressure, diastolic blood pressure and systolic blood pressure and hemoglobin saturation from oxygen are measured at these times. Intervention 2: Control group: After obtaining a license from the Medical Ethics Committee of Isfahan University of Medical Sciences, patients who are willing to participate in the study. In the first period  with the package  (a) containing 1.5 mg / kg of ketamine and mg/kg 0.5 of succinylcholine  and in the second period with the package (b) containing 1.5 mg / kg of ketamine and 50 μg / kg of cis-atracurium  taken under electroshock therapy. And from the right hand, blood samples are taken at the time before administration of the anesthetic drug (baseline) before induction of the electroshock (after administration of the drug), after the seizure, and 20 minutes after induction of anesthesia. before induction Anesthesia is provided for patients with a simple oxygen mask and given 4 to 6 liters of oxygen for a period of three minutes. Heart monitoring includes electro-cardiogram and heart rate, pulse oximetry and non-invasive blood pressure for all patients. Heart rate, mean arterial blood pressure, diastolic blood pressure and systolic blood pressure and hemoglobin saturation from oxygen are measured at these times.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is Need to gather more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Atefeh Ghosouri</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>dehkhoda street</address>
        <city>shahinshahr</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8316673200</zip>
        <telephone>+98 31 4536 2385</telephone>
        <email>ghosouriatefeh@gmail.com</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Behzad Nazemalroaya</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Soffeh boulevard, Shahid Keshvari highway</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8174675731</zip>
        <telephone>+98 36202020</telephone>
        <email>behzad_nazem@med.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>People under the age of 18
American Society of Anesthesiology physical status class 1,2</inclusion_criteria>
      <agemin>11 years</agemin>
      <agemax>18 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Obesity (index is equal to or greater than 30
History of asthma
Allergy
Myocardial infarction in the last 6 months
Stroke in the last 6 weeks
Fibrillation and cardiac flutter
Repeated ectopic treatment at the same session
Having diseases like high blood pressure and hyperactivity</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>T48.1X3</hc_code>
      <hc_code>T48.1X3</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], assault</hc_keyword>
      <hc_keyword>Poisoning by skeletal muscle relaxants [neuromuscular blocking agents], assault</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: After obtaining a license from the Medical Ethics Committee of Isfahan University of Medical Sciences, patients who are willing to participate in the study. In the first period  with the package  (b) containing 1.5 mg / kg of ketamine and 50 μg / kg of cis-atracurium and in the second period with the package (a) containing 1.5 mg / kg of ketamine and mg/kg 0.5 of succinylcholine taken under electroshock therapy. And from the right hand, blood samples are taken at the time before administration of the anesthetic drug (baseline) before induction of the electroshock  (after administration of the drug), after the seizure, and 20 minutes after induction of anesthesia. before induction Anesthesia is provided for patients with a simple oxygen mask and given 4 to 6 liters of oxygen for a period of three minutes. Heart monitoring includes electro-cardiogram and heart rate, pulse oximetry and non-invasive blood pressure for all patients. Heart rate, mean arterial blood pressure, diastolic blood pressure and systolic blood pressure and hemoglobin saturation from oxygen are measured at these times.</i_keyword>
      <i_keyword>Control group: After obtaining a license from the Medical Ethics Committee of Isfahan University of Medical Sciences, patients who are willing to participate in the study. In the first period  with the package  (a) containing 1.5 mg / kg of ketamine and mg/kg 0.5 of succinylcholine  and in the second period with the package (b) containing 1.5 mg / kg of ketamine and 50 μg / kg of cis-atracurium  taken under electroshock therapy. And from the right hand, blood samples are taken at the time before administration of the anesthetic drug (baseline) before induction of the electroshock (after administration of the drug), after the seizure, and 20 minutes after induction of anesthesia. before induction Anesthesia is provided for patients with a simple oxygen mask and given 4 to 6 liters of oxygen for a period of three minutes. Heart monitoring includes electro-cardiogram and heart rate, pulse oximetry and non-invasive blood pressure for all patients. Heart rate, mean arterial blood pressure, diastolic blood pressure and systolic blood pressure and hemoglobin saturation from oxygen are measured at these times.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Serum potassium levels. Timepoint: Before the administration of the anesthetic (baseline), before induction of the  Electroshock  (after administration of the drug), after the seizure, and 20 minutes after induction of anesthesia. Method of measurement: potassium test.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Heart rate changes. Timepoint: Before the administration of the anesthetic (baseline), before induction of the electroshock (after administration of the drug), after the seizure, and 20 minutes after induction of anesthesia. Method of measurement: Heart monitoring.</sec_outcome>
      <sec_outcome>Systolic blood pressure. Timepoint: Before the administration of the anesthetic (baseline), before induction of the electroshock (after administration of the drug), after the seizure, and 20 minutes after induction of anesthesia. Method of measurement: Non invasive blood pressure monitor.</sec_outcome>
      <sec_outcome>Diastolic blood pressure. Timepoint: Before the administration of the anesthetic (baseline), before induction of the electroshock (after administration of the drug), after the seizure, and 20 minutes after induction of anesthesia. Method of measurement: Non invasive blood pressure monitor.</sec_outcome>
      <sec_outcome>Mean arterial pressure. Timepoint: Before the administration of the anesthetic (baseline), before induction of the electroshock (after administration of the drug), after the seizure, and 20 minutes after induction of anesthesia. Method of measurement: Non invasive blood pressure monitor.</sec_outcome>
      <sec_outcome>Oxygen saturation. Timepoint: Before the administration of the anesthetic (baseline), before induction of the electroshock (after administration of the drug), after the seizure, and 20 minutes after induction of anesthesia. Method of measurement: Percent with pulse oximeter.</sec_outcome>
      <sec_outcome>Recovery time. Timepoint: From the end of seizure to full consciousness. Method of measurement: In minutes using a stopwatch.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Esfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-02-27</approval_date>
        <contact_name>Ethics committee of Isfahan University of Medical Sciences</contact_name>
        <contact_address>Hezar jarib street Isfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
